Patents Assigned to CELLIX BIO PRIVATE LIMITED
-
Publication number: 20240082162Abstract: The present invention relates to a pharmaceutical formulations and compositions comprising cholinergic agonist agents such as pilocarpine-R-(+)-lipoate or its salt, solvate, or hydrate thereof for oral administration with improved compliance, safety, and bioavailability. It further discloses methods of preparing the formulations and its use for the treatment of xerostomia, dry mouth and Sjogren's syndrome.Type: ApplicationFiled: May 25, 2021Publication date: March 14, 2024Applicant: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Patent number: 11903992Abstract: The present disclosure provides a composition comprising Lidocaine or salt or hydrate or solvate thereof, L-Carnosine or salt or hydrate or solvate thereof and dexpanthenol or salt or hydrate or solvate thereof. The composition may further comprise one or more other active agents. In an embodiment, the composition is formulated as an oral formulation. The compositions of the present disclosure may find utility in treatment of oral mucositis, ulcers, ulcer mediated pain and the like conditions. Aspects of the present disclosure also relates to method of treating oral, pharyngeal, oropharyngeal and esophageal diseases or conditions using the advantageous compositions of the present disclosure.Type: GrantFiled: February 10, 2022Date of Patent: February 20, 2024Assignee: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Publication number: 20230310391Abstract: The present disclosure relates to pharmaceutical compositions comprising a therapeutically effective amount of an antimuscarinic or an anticholinergic agent or a pharmaceutically acceptable salt or a stereoisomer thereof in combination with a therapeutically effective amount of lipoic acid or a pharmaceutically acceptable salt or a stereoisomer thereof. The antimuscarinic or anticholinergic agent is a compound of Formula I, Formula II, or Formula III and lipoic acid is a compound of Formula IV or Formula V. The Pharmaceutical composition is a physical mixture of an antimuscarinic or an anticholinergic agent and lipoic acid.Type: ApplicationFiled: November 23, 2022Publication date: October 5, 2023Applicant: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Publication number: 20230219936Abstract: The present invention discloses a large scale process for preparation of triazole compounds using polar and non-polar solvents. More particularly relates to s method of preparing dilauryl glyceryl fumarate salt of posaconazole, voriconazole and itraconazole respectively. The method comprises of dissolving triazole compound and dilauryl glyceryl fumarate in a suitable polar solvent at a temperature range of 30-55° C. for salt formation and final salt is isolated using non-polar solvent at a low temperature range of 0-35° C. It further discloses a method of producing fine particulate size of the dilauryl glyceryl fumarate salt of triazole preferably in the size ranging from 0.001 micron to 100 micron. It also discloses a method of preparing a desired pharmaceutical preparation.Type: ApplicationFiled: May 4, 2021Publication date: July 13, 2023Applicant: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Patent number: 11649215Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.Type: GrantFiled: January 14, 2022Date of Patent: May 16, 2023Assignee: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Patent number: 11643419Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV and formula V and the methods for the treatment of xerostomia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral mucosal inflammatory, dry mouth or oral dry mouth mediated infectious diseases.Type: GrantFiled: April 19, 2017Date of Patent: May 9, 2023Assignee: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Patent number: 11555007Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II and formula III and the methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, nasal spray, oral solution, suspension, oral spray, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of neurological diseases.Type: GrantFiled: October 18, 2020Date of Patent: January 17, 2023Assignee: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Patent number: 11485730Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.Type: GrantFiled: January 10, 2022Date of Patent: November 1, 2022Assignee: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Publication number: 20220340551Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.Type: ApplicationFiled: January 10, 2022Publication date: October 27, 2022Applicant: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Publication number: 20220324813Abstract: The present invention relates to compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers, prodrugs, hydrates and or derivatives thereof. The Pharmaceutical composition comprises an effective amount of compounds of formula I, formula II, formula III, formula IV, Formula V, formula VI or formula VII and the methods of using the composition for treating disorder affecting the anus and rectum. The composition can be formulated for oral administration, rectal administration, topical administration, transmucosal, transdermal administration, spray, injection or other known formulation in the art.Type: ApplicationFiled: July 16, 2020Publication date: October 13, 2022Applicant: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Patent number: 11465973Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.Type: GrantFiled: October 8, 2020Date of Patent: October 11, 2022Assignee: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Publication number: 20220233508Abstract: The present disclosure provides a pharmaceutical composition comprising Famotidine or salt or hydrates or solvates thereof, Lidocaine or salt or hydrates or solvates thereof, and Melatonin or salt or hydrates or solvates thereof. The compositions of the present disclosure may find utility in treatment of oral mucositis, gastritis, gastric ulcers and the like conditions. Aspects of the present disclosure also relates to method of treating oral and gastrointestinal diseases/conditions using the advantageous compositions of the present disclosure.Type: ApplicationFiled: September 28, 2021Publication date: July 28, 2022Applicant: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Publication number: 20220233504Abstract: The present disclosure provides a pharmaceutical composition comprising Lidocaine or salt or hydrates or solvates thereof and Melatonin or salt or hydrates or solvates thereof. The compositions of the present disclosure may find utility in treatment of mucositis, oral mucositis, ulcers, ulcer mediated pain and the like conditions. Aspects of the present disclosure also relates to method of treating oral and gastrointestinal disease/conditions using the advantageous compositions of the present disclosure.Type: ApplicationFiled: September 28, 2021Publication date: July 28, 2022Applicant: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Publication number: 20220233629Abstract: The present disclosure provides a composition comprising Lidocaine or salt or hydrate or solvate thereof, L-Carnosine or salt or hydrate or solvate thereof and dexpanthenol or salt or hydrate or solvate thereof. The composition may further comprise one or more other active agents. In an embodiment, the composition is formulated as an oral formulation. The compositions of the present disclosure may find utility in treatment of oral mucositis, ulcers, ulcer mediated pain and the like conditions. Aspects of the present disclosure also relates to method of treating oral, pharyngeal, oropharyngeal and esophageal diseases or conditions using the advantageous compositions of the present disclosure.Type: ApplicationFiled: February 10, 2022Publication date: July 28, 2022Applicant: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Publication number: 20220220079Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.Type: ApplicationFiled: October 8, 2020Publication date: July 14, 2022Applicant: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Publication number: 20220213073Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.Type: ApplicationFiled: January 10, 2022Publication date: July 7, 2022Applicant: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Publication number: 20220213043Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.Type: ApplicationFiled: January 14, 2022Publication date: July 7, 2022Applicant: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Publication number: 20220193054Abstract: The present disclosure provides a pharmaceutical composition comprising Fexofenadine or salt or hydrates or solvates thereof, Famotidine or salt or hydrates or solvates thereof, and Melatonin or salt or hydrates or solvates thereof. The compositions of the present disclosure may find utility in treatment of urticaria, atopic dermatitis, pruritus and the like acute or chronic allergic reactions and/or dermatological diseases/conditions, and sleep disorders. Aspects of the present disclosure also relates to a method of treating inflammation associated with COVID 19, gastrointestinal diseases, urticaria, atopic dermatitis, pruritus and the like acute or chronic allergic reactions and/or dermatological diseases/conditions, and sleep disorders using the advantageous compositions of the present disclosure.Type: ApplicationFiled: September 28, 2021Publication date: June 23, 2022Applicant: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Publication number: 20220184052Abstract: The present disclosure provides a liquid formulation meant for nasal administration that includes fexofenadine or a salt or a hydrate or a solvate thereof. The compositions of the present disclosure may find utility in treatment of allergic conditions/diseases. The liquid formulation of the present disclosure gets converted into a gel upon its administration in the nasal region and releases the active agent locally in a sustained manner, while providing moisturizing effect and forming a layer on the nasal mucosa that acts like a barrier to entry of pathogens and allergens inhibiting their invasion into sinuses and deep layers of lining of the nose. Aspects of the present disclosure also relates to method of treating an allergic condition using the advantageous compositions of the present disclosure.Type: ApplicationFiled: February 10, 2022Publication date: June 16, 2022Applicant: Cellix Bio Private LimitedInventor: Mahesh Kandula
-
Patent number: 11312707Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.Type: GrantFiled: November 24, 2017Date of Patent: April 26, 2022Assignee: Cellix Bio Private LimitedInventor: Mahesh Kandula